Key result
Navitor valve demonstrates high technical success with ~2% 30-day mortality, stroke, and PVL rates.
Why the study?
Midterm outcomes and safety profile of the Self-Expanding Navitor Transcatheter Heart Valve have not been comprehensively synthesized.
What are the midterm clinical and procedural outcomes of the self-expanding Navitor transcatheter heart valve?
What are the midterm clinical and procedural outcomes of the self-expanding Navitor transcatheter heart valve?
The self-expanding Navitor transcatheter heart valve demonstrates high technical success and favorable 30-day mortality and stroke rates, with very low rates of significant paravalvular leak, though pacemaker implantation rates remain notable.
Supports Navitor adoption in TAVR; extends pooled evidence for next-generation self-expanding valves.
•A 19-study meta-analysis (7743 patients) found high Navitor technical/device success.•≥Moderate PVL was low: 1.3% at 30 days and 0.6% at 1 year.•Pacemaker implantation was 16.7% at 30 days and 20.4% at 1 year.•Thirty-day outcomes were favorable: all-cause mortality 1.5% and stroke 1.7%.
No takes yet. Share an insight, caveat, or question.
Samimi et al. (2025) studied this question. The Navitor transcatheter heart valve demonstrated high technical success with low 30-day rates of all-cause mortality (1.5%), stroke (1.7%), and ≥moderate paravalvular leak (1.3%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: